Similar articles

• RE: Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.

  Walsh PC. Walsh PC. J Natl Cancer Inst. 2019 Jul 1;111(7):747. doi: 10.1093/jnci/djy186. J Natl Cancer Inst. 2019. PMID: 30380081 No abstract available.
• Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

  Thompson I Jr, Goodman P, Tangen C. Thompson I Jr, et al. J Natl Cancer Inst. 2018 Nov 1;110(11):1159-1160. doi: 10.1093/jnci/djy038. J Natl Cancer Inst. 2018. PMID: 29547919 Free PMC article. No abstract available.
• Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.

  Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A. Murtola TJ, et al. J Urol. 2017 Aug;198(2):305-309. doi: 10.1016/j.juro.2017.02.069. Epub 2017 Feb 16. J Urol. 2017. PMID: 28216328 Clinical Trial.
• Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

  van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH. van Leeuwen PJ, et al. Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Eur Urol. 2011. PMID: 21130560 Review.
• The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. Marks LS, et al. J Urol. 2006 Sep;176(3):868-74. doi: 10.1016/j.juro.2006.04.024. J Urol. 2006. PMID: 16890642 Review.